iBio Inc (IBIO) — Titan Protect Analysis

IBIO

iBio Inc

Healthcare · ·

$1.82

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$88M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-5.59

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-62.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$5.50

+202% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 6 analysts covering this stock

About iBio Inc

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai

https://ibioinc.com

Country: United States Employees: 20 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.482

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0122

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.128

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-11.7%

Historical annualised return based on price data

Max Drawdown

-91.1%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$3.82

52% below the year high

52W Low

$0.56

225% above the year low

Avg Volume

938,679

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.56

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

3.00

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-9,653.0%

Profit from core operations before interest and tax

Free Cash Flow

$-14,936,750

Negative — the business is spending more than it generates

Revenue (TTM)

$300,000

Total revenue over the last 12 months

Net Income

$-27,606,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$7.00

Target Median

$5.50

Target Low

$4.20

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go